Related Experiment Video

Updated: May 22, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment

M Weiler1, P-N Pfenning, A-L Thiepold

  • 1Clinical Cooperation Unit Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany.

Oncogene
|May 8, 2012
PubMed

Insights

Combining radiotherapy with mammalian target of rapamycin (mTOR) inhibition, like temsirolimus, shows promise for glioblastoma treatment. This approach enhances survival by reducing tumor cell invasion and overcoming resistance mechanisms.

Area of Science:

  • Oncology
  • Cancer Research
  • Molecular Biology

Background:

  • Radiotherapy (RT) resistance in glioblastoma can be driven by increased tumor cell motility and invasiveness.
  • Targeting cell motility presents a strategy to enhance RT efficacy.
  • Mammalian target of rapamycin (mTOR) signaling is implicated in cancer progression and invasion.

Purpose of the Study:

  • To investigate the efficacy of combining focal radiotherapy with mTOR inhibition using temsirolimus (CCI-779) in a mouse glioma model.
  • To elucidate the mechanisms underlying the anti-invasive effects of mTOR inhibition in glioblastoma.
  • To identify potential therapeutic targets for overcoming RT resistance.

Main Methods:

  • Utilized a syngeneic mouse glioma model to assess survival outcomes.
  • Performed in vitro experiments to evaluate the effects of temsirolimus on glioblastoma cell invasion, with and without RT.
  • Investigated the role of regulator of G-protein signaling 4 (RGS4) as a downstream target of mTOR inhibition.

Main Results:

  • The combination of RT and temsirolimus significantly prolonged survival in the mouse glioma model.
  • Temsirolimus demonstrated potent anti-invasive effects in vitro, counteracting RT-induced invasiveness.
  • Regulator of G-protein signaling 4 (RGS4) was identified as a key mediator of glioblastoma invasion, targeted by mTOR inhibition.
  • Both mTORC1 and mTORC2 complexes were involved in RGS4-dependent invasion suppression.

Conclusions:

  • Combined RT and mTOR inhibition represents a promising therapeutic strategy for glioblastoma.
  • This combination may overcome tumor cell resistance mechanisms associated with RT.
  • Further clinical investigation of upfront glioblastoma therapy combining RT and mTOR inhibition is warranted.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...